

Charles A Dinarello

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4824730/publications.pdf>

Version: 2024-02-01

240
papers

44,422
citations

3116

95
h-index

2453

203
g-index

249
all docs

249
docs citations

249
times ranked

56376
citing authors

#	ARTICLE	IF	CITATIONS
1	IL-37 regulates allergic inflammation by counterbalancing pro-inflammatory IL-1 and IL-33. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 856-869.	2.7	25
2	The NLRP3 inflammasome inhibitor, OLT1177 [®] , ameliorates experimental allergic asthma in mice. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 1035-1038.	2.7	17
3	Inhibition of the NLRP3 inflammasome by OLT1177 induces functional protection and myelin preservation after spinal cord injury. <i>Experimental Neurology</i> , 2022, 347, 113889.	2.0	14
4	IL-1 family cytokines as drivers and inhibitors of trained immunity. <i>Cytokine</i> , 2022, 150, 155773.	1.4	25
5	Anakinra restores cellular proteostasis by coupling mitochondrial redox balance to autophagy. <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	7
6	Interleukin-38 in Health and Disease. <i>Cytokine</i> , 2022, 152, 155824.	1.4	15
7	Activation of Host-NLRP3 Inflammasome in Myeloid Cells Dictates Response to Anti-PD-1 Therapy in Metastatic Breast Cancers. <i>Pharmaceuticals</i> , 2022, 15, 574.	1.7	9
8	Abstract A026: Altered immune landscape in aging lungs contributes to malignant evolution. <i>Cancer Research</i> , 2022, 82, A026-A026.	0.4	0
9	IL-38 Gene Deletion Worsens Murine Colitis. <i>Frontiers in Immunology</i> , 2022, 13, .	2.2	11
10	Human and Bacterial Toll-Interleukin Receptor Domains Exhibit Distinct Dynamic Features and Functions. <i>Molecules</i> , 2022, 27, 4494.	1.7	2
11	IL-37 exerts therapeutic effects in experimental autoimmune encephalomyelitis through the receptor complex IL-1R5/IL-1R8. <i>Theranostics</i> , 2021, 11, 1-13.	4.6	13
12	IL-18 and infections: Is there a role for targeted therapies?. <i>Journal of Cellular Physiology</i> , 2021, 236, 1638-1657.	2.0	83
13	Alpha-1 antitrypsin governs alcohol-related liver disease in mice and humans. <i>Gut</i> , 2021, 70, 585-594.	6.1	6
14	Extracellular and nuclear roles of IL-37 after spinal cord injury. <i>Brain, Behavior, and Immunity</i> , 2021, 91, 194-201.	2.0	11
15	Reduced concentrations of the B cell cytokine interleukin 38 are associated with cardiovascular disease risk in overweight subjects. <i>European Journal of Immunology</i> , 2021, 51, 662-671.	1.6	23
16	Human recombinant interleukin-38 suppresses inflammation in mouse models of local and systemic disease. <i>Cytokine</i> , 2021, 137, 155334.	1.4	16
17	A novel anti-human IL-1R7 antibody reduces IL-18-mediated inflammatory signaling. <i>Journal of Biological Chemistry</i> , 2021, 296, 100630.	1.6	12
18	IL-38 prevents induction of trained immunity by inhibition of mTOR signaling. <i>Journal of Leukocyte Biology</i> , 2021, 110, 907-915.	1.5	20

#	ARTICLE	IF	CITATIONS
19	Targeting tumor-derived NLRP3 reduces melanoma progression by limiting MDSCs expansion. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	95
20	Modulation of Liver Inflammation and Fibrosis by Interleukin-37. <i>Frontiers in Immunology</i> , 2021, 12, 603649.	2.2	30
21	Interleukin 1 \pm : a comprehensive review on the role of IL-1 \pm in the pathogenesis and treatment of autoimmune and inflammatory diseases. <i>Autoimmunity Reviews</i> , 2021, 20, 102763.	2.5	140
22	Chronic HIV infection induces transcriptional and functional reprogramming of innate immune cells. <i>JCI Insight</i> , 2021, 6, .	2.3	33
23	The anti-inflammatory cytokine interleukin-37 is an inhibitor of trained immunity. <i>Cell Reports</i> , 2021, 35, 108955.	2.9	40
24	Editorial: Cytokines and Intestinal Mucosal Immunity. <i>Frontiers in Immunology</i> , 2021, 12, 698693.	2.2	3
25	Impact of rare and common genetic variation in the interleukin-1 pathway on human cytokine responses. <i>Genome Medicine</i> , 2021, 13, 94.	3.6	5
26	Oncogene-induced maladaptive activation of trained immunity in the pathogenesis and treatment of Erdheim-Chester disease. <i>Blood</i> , 2021, 138, 1554-1569.	0.6	10
27	Interleukins in cancer: from biology to therapy. <i>Nature Reviews Cancer</i> , 2021, 21, 481-499.	12.8	318
28	Tumor NLRP3-Derived IL-1 β Drives the IL-6/STAT3 Axis Resulting in Sustained MDSC-Mediated Immunosuppression. <i>Frontiers in Immunology</i> , 2021, 12, 661323.	2.2	44
29	Single-cell RNA-seq reveals a critical role of novel pro-inflammatory EndMT in mediating adverse remodeling in coronary artery "on a" "chip. <i>Science Advances</i> , 2021, 7, .	4.7	21
30	Interleukin 1 receptor antagonism abrogates acute pressure-overload induced murine heart failure. <i>Annals of Thoracic Surgery</i> , 2021, , .	0.7	3
31	Interleukin-37 improves T α cell-mediated immunity and chimeric antigen receptor T α cell therapy in aged backgrounds. <i>Aging Cell</i> , 2021, 20, e13309.	3.0	14
32	Pro-inflammatory cytokine blockade attenuates myeloid expansion in a murine model of rheumatoid arthritis. <i>Haematologica</i> , 2020, 105, 585-597.	1.7	32
33	PASylation of IL-1 receptor antagonist (IL-1Ra) retains IL-1 blockade and extends its duration in mouse urate crystal-induced peritonitis. <i>Journal of Biological Chemistry</i> , 2020, 295, 868-882.	1.6	10
34	Short-term interleukin-37 treatment improves vascular endothelial function, endurance exercise capacity, and whole-body glucose metabolism in old mice. <i>Aging Cell</i> , 2020, 19, e13074.	3.0	37
35	Dapansutrile, an oral selective NLRP3 inflammasome inhibitor, for treatment of gout flares: an open-label, dose-adaptive, proof-of-concept, phase 2a trial. <i>Lancet Rheumatology</i> , The, 2020, 2, e270-e280.	2.2	130
36	The NLRP3 inflammasome inhibitor OLT1177 rescues cognitive impairment in a mouse model of Alzheimer's disease. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 32145-32154.	3.3	150

#	ARTICLE	IF	CITATIONS
37	Early IL-1 receptor blockade in severe inflammatory respiratory failure complicating COVID-19. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 18951-18953.	3.3	173
38	Inflammasome Sensor NLRP1 Confers Acquired Drug Resistance to Temozolomide in Human Melanoma. Cancers, 2020, 12, 2518.	1.7	16
39	Rare genetic variants in interleukin-37 link this anti-inflammatory cytokine to the pathogenesis and treatment of gout. Annals of the Rheumatic Diseases, 2020, 79, 536-544.	0.5	44
40	Interleukin-1 and the Inflammasome as Therapeutic Targets in Cardiovascular Disease. Circulation Research, 2020, 126, 1260-1280.	2.0	391
41	PASylation of IL-1 receptor antagonist (IL-1Ra) retains IL-1 blockade and extends its duration in mouse urate crystal-induced peritonitis. Journal of Biological Chemistry, 2020, 295, 868-882.	1.6	17
42	IL-37 Expression Is Downregulated in Lesional Psoriasis Skin. ImmunoHorizons, 2020, 4, 754-761.	0.8	18
43	IL-1R3 blockade broadly attenuates the functions of six members of the IL-1 family, revealing their contribution to models of disease. Nature Immunology, 2019, 20, 1138-1149.	7.0	55
44	The Significance of IL-36 Hyperactivation and IL-36R Targeting in Psoriasis. International Journal of Molecular Sciences, 2019, 20, 3318.	1.8	91
45	Targeting innate immune mediators in type 1 and type 2 diabetes. Nature Reviews Immunology, 2019, 19, 734-746.	10.6	237
46	Interleukin-37 is highly expressed in regulatory T cells of melanoma patients and enhanced by melanoma cell secretome. Molecular Carcinogenesis, 2019, 58, 1670-1679.	1.3	19
47	Interleukin-1 and Related Cytokines in the Regulation of Inflammation and Immunity. Immunity, 2019, 50, 778-795.	6.6	639
48	Role for nuclear interleukin-37 in the suppression of innate immunity. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 4456-4461.	3.3	38
49	Efficacy of canakinumab as first-line biologic agent in adult-onset Still's disease. Arthritis Research and Therapy, 2019, 21, 54.	1.6	31
50	Interleukin-37 monomer is the active form for reducing innate immunity. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 5514-5522.	3.3	38
51	OLT1177 (Dapansutrile), a Selective NLRP3 Inflammasome Inhibitor, Ameliorates Experimental Autoimmune Encephalomyelitis Pathogenesis. Frontiers in Immunology, 2019, 10, 2578.	2.2	69
52	Interleukin-37 Inhibits Colon Carcinogenesis During Chronic Colitis. Frontiers in Immunology, 2019, 10, 2632.	2.2	10
53	Neutralization of IL-1 β ameliorates Crohn's disease-like ileitis by functional alterations of the gut microbiome. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 26717-26726.	3.3	41
54	Interleukin-1 receptor antagonist levels predict favorable outcome after bermekimab, a first-in-class true human interleukin-1 β antibody, in a phase III randomized study of advanced colorectal cancer. OncoImmunology, 2019, 8, 1551651.	2.1	33

#	ARTICLE	IF	CITATIONS
55	Blocking IL-1 ^{Î²} reverses the immunosuppression in mouse breast cancer and synergizes with anti-PD-1 for tumor abrogation. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 1361-1369.	3.3	302
56	Treatment of HIV-Infected Individuals with the Histone Deacetylase Inhibitor Panobinostat Results in Increased Numbers of Regulatory T Cells and Limits <i>Ex Vivo</i> Lipopolysaccharide-Induced Inflammatory Responses. MSphere, 2018, 3, .	1.3	17
57	Human Interleukin-32 ^{Î³} Plays a Protective Role in an Experimental Model of Visceral Leishmaniasis in Mice. Infection and Immunity, 2018, 86, .	1.0	14
58	Treatment of Inflammatory Diseases with IL-1 Blockade. Current Otorhinolaryngology Reports, 2018, 6, 1-14.	0.2	7
59	Role of glutathione metabolism in host defense against <i>Borrelia burgdorferi</i> infection. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E2320-E2328.	3.3	31
60	OLT1177, a ^{Î²} -sulfonyl nitrile compound, safe in humans, inhibits the NLRP3 inflammasome and reverses the metabolic cost of inflammation. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E1530-E1539.	3.3	346
61	Histone deacetylase activity governs diastolic dysfunction through a nongenomic mechanism. Science Translational Medicine, 2018, 10, .	5.8	114
62	MABp1 Targeting IL-1 ^{Î±} for Moderate to Severe Hidradenitis Suppurativa Not Eligible for Adalimumab: A Randomized Study. Journal of Investigative Dermatology, 2018, 138, 795-801.	0.3	88
63	Introduction to the interleukin-1 family of cytokines and receptors: Drivers of innate inflammation and acquired immunity. Immunological Reviews, 2018, 281, 5-7.	2.8	57
64	Suppression of inflammation and acquired immunity by IL-37. Immunological Reviews, 2018, 281, 179-190.	2.8	225
65	Biology of IL-38 and its role in disease. Immunological Reviews, 2018, 281, 191-196.	2.8	81
66	Overview of the IL-1 family in innate inflammation and acquired immunity. Immunological Reviews, 2018, 281, 8-27.	2.8	1,206
67	Interleukin-32 upregulates the expression of ABCA1 and ABCG1 resulting in reduced intracellular lipid concentrations in primary human hepatocytes. Atherosclerosis, 2018, 271, 193-202.	0.4	18
68	Anakinra Therapy for Non-cancer Inflammatory Diseases. Frontiers in Pharmacology, 2018, 9, 1157.	1.6	198
69	The Inter-Relationship of Platelets with Interleukin-1 ^{Î²} -Mediated Inflammation in Humans. Thrombosis and Haemostasis, 2018, 118, 2112-2125.	1.8	35
70	Interleukin-1 ^{Î±} as an intracellular alarmin in cancer biology. Seminars in Immunology, 2018, 38, 3-14.	2.7	26
71	IL-38 has an anti-inflammatory action in psoriasis and its expression correlates with disease severity and therapeutic response to anti-IL-17A treatment. Cell Death and Disease, 2018, 9, 1104.	2.7	104
72	TLR9 and IL-1R1 Promote Mobilization of Pulmonary Dendritic Cells during Beryllium Sensitization. Journal of Immunology, 2018, 201, 2232-2243.	0.4	15

#	ARTICLE	IF	CITATIONS
73	NLRP3 inflammasome inhibitor OLT1177 suppresses joint inflammation in murine models of acute arthritis. <i>Arthritis Research and Therapy</i> , 2018, 20, 169.	1.6	110
74	Interleukin-37 treatment of mice with metabolic syndrome improves insulin sensitivity and reduces pro-inflammatory cytokine production in adipose tissue. <i>Journal of Biological Chemistry</i> , 2018, 293, 14224-14236.	1.6	42
75	The selective ROCK2 inhibitor KDO25 reduces IL-17 secretion in human peripheral blood mononuclear cells independent of IL-1 and IL-6. <i>European Journal of Immunology</i> , 2018, 48, 1679-1686.	1.6	15
76	Interleukin 37 expression in mice alters sleep responses to inflammatory agents and influenza virus infection. <i>Neurobiology of Sleep and Circadian Rhythms</i> , 2017, 3, 1-9.	1.4	15
77	IL-32 promoter SNP rs4786370 predisposes to modified lipoprotein profiles in patients with rheumatoid arthritis. <i>Scientific Reports</i> , 2017, 7, 41629.	1.6	20
78	Interleukin-37 suppresses the osteogenic responses of human aortic valve interstitial cells in vitro and alleviates valve lesions in mice. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, 1631-1636.	3.3	91
79	Abnormal epigenetic changes during differentiation of human skeletal muscle stem cells from obese subjects. <i>BMC Medicine</i> , 2017, 15, 39.	2.3	51
80	Interleukin-37 suppresses the inflammatory response to protect cardiac function in old endotoxemic mice. <i>Cytokine</i> , 2017, 95, 55-63.	1.4	25
81	Cytokine Inhibition in Patients With Chronic Fatigue Syndrome. <i>Annals of Internal Medicine</i> , 2017, 166, 557.	2.0	30
82	Interleukin 37 reverses the metabolic cost of inflammation, increases oxidative respiration, and improves exercise tolerance. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, 2313-2318.	3.3	87
83	Uric acid priming in human monocytes is driven by the AKT-PRAS40 autophagy pathway. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, 5485-5490.	3.3	114
84	Myeloid-derived miR-223 regulates intestinal inflammation via repression of the NLRP3 inflammasome. <i>Journal of Experimental Medicine</i> , 2017, 214, 1737-1752.	4.2	289
85	IL-18 binding protein reverses the life-threatening hyperinflammation of a baby with the NLRC4 mutation. <i>Journal of Allergy and Clinical Immunology</i> , 2017, 140, 316.	1.5	12
86	A guiding map for inflammation. <i>Nature Immunology</i> , 2017, 18, 826-831.	7.0	506
87	Vorinostat plus tacrolimus/methotrexate to prevent GVHD after myeloablative conditioning, unrelated donor HCT. <i>Blood</i> , 2017, 130, 1760-1767.	0.6	57
88	Interleukin-32 in chronic inflammatory conditions is associated with a higher risk of cardiovascular diseases. <i>Atherosclerosis</i> , 2017, 264, 83-91.	0.4	46
89	Interleukin-1 as a mediator of fatigue in disease: a narrative review. <i>Journal of Neuroinflammation</i> , 2017, 14, 16.	3.1	60
90	IL-1 Inhibition and Vascular Function in CKD. <i>Journal of the American Society of Nephrology: JASN</i> , 2017, 28, 971-980.	3.0	66

#	ARTICLE	IF	CITATIONS
91	IL-1 Superfamily and Inflammasome. , 2017, , 477-528.		3
92	Interleukin-1 Receptor Blockade Rescues Myocarditis-Associated End-Stage Heart Failure. <i>Frontiers in Immunology</i> , 2017, 8, 131.	2.2	53
93	Gp96 Peptide Antagonist gp96-II Confers Therapeutic Effects in Murine Intestinal Inflammation. <i>Frontiers in Immunology</i> , 2017, 8, 1531.	2.2	7
94	Human Alpha-1-Antitrypsin (hAAT) therapy reduces renal dysfunction and acute tubular necrosis in a murine model of bilateral kidney ischemia-reperfusion injury. <i>PLoS ONE</i> , 2017, 12, e0168981.	1.1	21
95	Implication of the intestinal microbiome as a potential surrogate marker of immune responsiveness to experimental therapies in autoimmune diabetes. <i>PLoS ONE</i> , 2017, 12, e0173968.	1.1	7
96	Cytokines and microbicidal molecules regulated by IL-32 in THP-1-derived human macrophages infected with New World Leishmania species. <i>PLoS Neglected Tropical Diseases</i> , 2017, 11, e0005413.	1.3	38
97	IL-32 ³ promotes the healing of murine cutaneous lesions caused by <i>Leishmania braziliensis</i> infection in contrast to <i>Leishmania amazonensis</i> . <i>Parasites and Vectors</i> , 2017, 10, 336.	1.0	18
98	IL-37 Suppresses MyD88-mediated Inflammatory Responses in Human Aortic Valve Interstitial Cells. <i>Molecular Medicine</i> , 2017, 23, 83-91.	1.9	36
99	Activation of Proteinase 3 Contributes to Nonalcoholic Fatty Liver Disease and Insulin Resistance. <i>Molecular Medicine</i> , 2016, 22, 202-214.	1.9	29
100	Î±-Linoleic Acid Enhances the Capacity of Î±1-Antitrypsin to Inhibit Lipopolysaccharide-Induced IL-1Î² in Human Blood Neutrophils. <i>Molecular Medicine</i> , 2016, 22, 680-693.	1.9	25
101	Reduction in C-reactive protein indicates successful targeting of the IL-1/IL-6 axis resulting in improved survival in early stage multiple myeloma. <i>American Journal of Hematology</i> , 2016, 91, 571-574.	2.0	75
102	Interleukin-1 Receptor Blockade Is Associated With Reduced Mortality in Sepsis Patients With Features of Macrophage Activation Syndrome. <i>Critical Care Medicine</i> , 2016, 44, 275-281.	0.4	659
103	Toll-like receptors and chronic inflammation in rheumatic diseases: new developments. <i>Nature Reviews Rheumatology</i> , 2016, 12, 344-357.	3.5	150
104	Understanding human immune function using the resources from the Human Functional Genomics Project. <i>Nature Medicine</i> , 2016, 22, 831-833.	15.2	63
105	Suppression of innate inflammation and immunity by interleukin-37. <i>European Journal of Immunology</i> , 2016, 46, 1067-1081.	1.6	189
106	Treating experimental arthritis with the innate immune inhibitor interleukin-37 reduces joint and systemic inflammation. <i>Rheumatology</i> , 2016, 55, 2220-2229.	0.9	77
107	Glutaminolysis and Fumarate Accumulation Integrate Immunometabolic and Epigenetic Programs in Trained Immunity. <i>Cell Metabolism</i> , 2016, 24, 807-819.	7.2	584
108	IL-1 receptor antagonist ameliorates inflammasome-dependent inflammation in murine and human cystic fibrosis. <i>Nature Communications</i> , 2016, 7, 10791.	5.8	201

#	ARTICLE	IF	CITATIONS
109	Innate immune cell activation and epigenetic remodeling in symptomatic and asymptomatic atherosclerosis in humans in vivo. <i>Atherosclerosis</i> , 2016, 254, 228-236.	0.4	163
110	Host and Environmental Factors Influencing Individual Human Cytokine Responses. <i>Cell</i> , 2016, 167, 1111-1124.e13.	13.5	364
111	Response of Steroid-Refractory Acute GVHD to Î± 1 -Antitrypsin. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1596-1601.	2.0	51
112	MHC class II super-enhancer increases surface expression of HLA-DR and HLA-DQ and affects cytokine production in autoimmune vitiligo. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 1363-1368.	3.3	88
113	Autoimmune vitiligo is associated with gain-of-function by a transcriptional regulator that elevates expression of HLA-A*02:01 in vivo. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 1357-1362.	3.3	46
114	Beneficial effects of IL-37 after spinal cord injury in mice. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 1411-1416.	3.3	75
115	New tools to tackle inflammatory arthritis. <i>Nature Reviews Rheumatology</i> , 2016, 12, 78-80.	3.5	16
116	Safety and Efficacy of Anakinra in Severe Hidradenitis Suppurativa. <i>JAMA Dermatology</i> , 2016, 152, 52.	2.0	205
117	Suppression of monosodium urate crystal-induced cytokine production by butyrate is mediated by the inhibition of class I histone deacetylases. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 593-600.	0.5	90
118	Alpha-1-anti-trypsin-Fc fusion protein ameliorates gouty arthritis by reducing release and extracellular processing of IL-1Î² and by the induction of endogenous IL-1Ra. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1219-1227.	0.5	63
119	Histone deacetylase inhibition regulates inflammation and enhances Tregs after allogeneic hematopoietic cell transplantation in humans. <i>Blood</i> , 2015, 125, 815-819.	0.6	95
120	Cytokine inhibition in chronic fatigue syndrome patients: study protocol for a randomized controlled trial. <i>Trials</i> , 2015, 16, 439.	0.7	7
121	The histone deacetylase inhibitor panobinostat lowers biomarkers of cardiovascular risk and inflammation in HIV patients. <i>Aids</i> , 2015, 29, 1195-1200.	1.0	20
122	Specific Inhibition of Histone Deacetylase 8 Reduces Gene Expression and Production of Proinflammatory Cytokines in Vitro and in Vivo. <i>Journal of Biological Chemistry</i> , 2015, 290, 2368-2378.	1.6	55
123	IL-37 requires the receptors IL-18RÎ± and IL-1R8 (SIGIRR) to carry out its multifaceted anti-inflammatory program upon innate signal transduction. <i>Nature Immunology</i> , 2015, 16, 354-365.	7.0	352
124	ATP-Induced IL-1Î² Specific Secretion: True Under Stringent Conditions. <i>Frontiers in Immunology</i> , 2015, 6, 54.	2.2	43
125	IL-1 Receptor Antagonist Chimeric Protein: Context-Specific and Inflammation-Restricted Activation. <i>Journal of Immunology</i> , 2015, 195, 1705-1712.	0.4	8
126	Treating rheumatological diseases and co-morbidities with interleukin-1 blocking therapies. <i>Rheumatology</i> , 2015, 54, kev269.	0.9	91

#	ARTICLE	IF	CITATIONS
127	Protective host defense against disseminated candidiasis is impaired in mice expressing human interleukin-37. <i>Frontiers in Microbiology</i> , 2015, 5, 762.	1.5	21
128	Normal Free Interleukin-18 (IL-18) Plasma Levels in Dengue Virus Infection and the Need To Measure Both Total IL-18 and IL-18 Binding Protein Levels. <i>Vaccine Journal</i> , 2015, 22, 650-655.	3.2	30
129	Neuroinflammation in Alzheimer's disease. <i>Lancet Neurology, The</i> , 2015, 14, 388-405.	4.9	4,129
130	Human IL-32 expression protects mice against a hypervirulent strain of <i>Mycobacterium tuberculosis</i> . <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 5111-5116.	3.3	43
131	IL-1 family members in the pathogenesis and treatment of metabolic disease: Focus on adipose tissue inflammation and insulin resistance. <i>Cytokine</i> , 2015, 75, 280-290.	1.4	194
132	IL-1-Antitrypsin Combines with Plasma Fatty Acids and Induces Angiotensin-like Protein 4 Expression. <i>Journal of Immunology</i> , 2015, 195, 3605-3616.	0.4	47
133	The history of fever, leukocytic pyrogen and interleukin-1. <i>Temperature</i> , 2015, 2, 8-16.	1.7	52
134	Innate Cytokines Dictate the Fate of Acute Intestinal Inflammation. <i>Gastroenterology</i> , 2015, 148, 248-250.	0.6	6
135	An anti-inflammatory property of <i>Candida albicans</i> β -glucan: Induction of high levels of interleukin-1 receptor antagonist via a Dectin-1/CR3 independent mechanism. <i>Cytokine</i> , 2015, 71, 215-222.	1.4	42
136	Anti-inflammatory therapies in acute coronary syndromes: is IL-1 blockade a solution?. <i>European Heart Journal</i> , 2015, 36, 337-339.	1.0	20
137	Leukocyte Activity in Patients with ST-Segment Elevation Acute Myocardial Infarction Treated with Anakinra. <i>Molecular Medicine</i> , 2014, 20, 486-489.	1.9	12
138	Acute-Phase Protein IL-1-Antitrypsin: A Novel Regulator of Angiotensin-like Protein 4 Transcription and Secretion. <i>Journal of Immunology</i> , 2014, 192, 5354-5362.	0.4	26
139	Role of caspase-1 in nuclear translocation of IL-37, release of the cytokine, and IL-37 inhibition of innate immune responses. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 2650-2655.	3.3	182
140	IL-1 receptor blockade restores autophagy and reduces inflammation in chronic granulomatous disease in mice and in humans. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 3526-3531.	3.3	273
141	Non-redundant properties of IL-1 α and IL-1 β during acute colon inflammation in mice. <i>Gut</i> , 2014, 63, 598-609.	6.1	205
142	IL-37 Inhibits Inflammasome Activation and Disease Severity in Murine Aspergillosis. <i>PLoS Pathogens</i> , 2014, 10, e1004462.	2.1	136
143	A Polysaccharide Virulence Factor from <i>Aspergillus fumigatus</i> Elicits Anti-inflammatory Effects through Induction of Interleukin-1 Receptor Antagonist. <i>PLoS Pathogens</i> , 2014, 10, e1003936.	2.1	117
144	Suppression of antigen-specific adaptive immunity by IL-37 via induction of tolerogenic dendritic cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 15178-15183.	3.3	151

#	ARTICLE	IF	CITATIONS
145	Deficient autophagy unravels the ROS paradox in chronic granulomatous disease. <i>Autophagy</i> , 2014, 10, 1141-1142.	4.3	47
146	Modulation of virus-induced innate immunity and type 1 diabetes by IL-1 blockade. <i>Innate Immunity</i> , 2014, 20, 574-584.	1.1	16
147	Clinical predictors of response to anakinra in patients with heart failure. <i>International Journal of Cardiology</i> , 2014, 173, 537-539.	0.8	7
148	Interleukin-1 blockade in rheumatoid arthritis and heart failure: A missed opportunity?. <i>International Journal of Cardiology</i> , 2014, 171, e125-e126.	0.8	17
149	Vorinostat plus tacrolimus and mycophenolate to prevent graft-versus-host disease after related-donor reduced-intensity conditioning allogeneic haemopoietic stem-cell transplantation: a phase 1/2 trial. <i>Lancet Oncology</i> , 2014, 15, 87-95.	5.1	113
150	Panobinostat, a histone deacetylase inhibitor, for latent-virus reactivation in HIV-infected patients on suppressive antiretroviral therapy: a phase 1/2, single group, clinical trial. <i>Lancet HIV</i> , 2014, 1, e13-e21.	2.1	542
151	IL-37 protects against obesity-induced inflammation and insulin resistance. <i>Nature Communications</i> , 2014, 5, 4711.	5.8	186
152	Interleukin-18 mediates interleukin-1-induced cardiac dysfunction. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2014, 306, H1025-H1031.	1.5	110
153	Interleukin-10 in patients with ST-segment elevation myocardial infarction. <i>International Journal of Cardiology</i> , 2014, 172, e6-e8.	0.8	9
154	IL-1-Antitrypsin (AAT)-modified donor cells suppress GVHD but enhance the GVL effect: a role for mitochondrial bioenergetics. <i>Blood</i> , 2014, 124, 2881-2891.	0.6	54
155	Interleukin-18, more than a Th1 cytokine. <i>Seminars in Immunology</i> , 2013, 25, 439-448.	2.7	236
156	Overview of the interleukin-1 family of ligands and receptors. <i>Seminars in Immunology</i> , 2013, 25, 389-393.	2.7	156
157	Treating inflammation by blocking interleukin-1 in humans. <i>Seminars in Immunology</i> , 2013, 25, 469-484.	2.7	471
158	The Interleukin-1 Family: Back to the Future. <i>Immunity</i> , 2013, 39, 1003-1018.	6.6	1,560
159	Interleukin-1 β in innate inflammation, autophagy and immunity. <i>Seminars in Immunology</i> , 2013, 25, 416-424.	2.7	107
160	Interleukin-37. <i>Seminars in Immunology</i> , 2013, 25, 466-468.	2.7	95
161	The Role of IL-1 β in the Early Tumor Cell-Induced Angiogenic Response. <i>Journal of Immunology</i> , 2013, 190, 3500-3509.	0.4	171
162	PS4 - 4. Proteinase 3: a new link between inflammation, obesity and Type 2 Diabetes. <i>Nederlands Tijdschrift Voor Diabetologie</i> , 2013, 11, 144-145.	0.0	0

#	ARTICLE	IF	CITATIONS
163	Interleukin-18 and IL-18 Binding Protein. <i>Frontiers in Immunology</i> , 2013, 4, 289.	2.2	714
164	PS21 - 102. IL-37 protects against obesity-induced inflammation and insulin resistance in mice. <i>Nederlands Tijdschrift Voor Diabetologie</i> , 2012, 10, 171-171.	0.0	0
165	IL-38 binds to the IL-36 receptor and has biological effects on immune cells similar to IL-36 receptor antagonist. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 3001-3005.	3.3	308
166	Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases. <i>Nature Reviews Drug Discovery</i> , 2012, 11, 633-652.	21.5	1,479
167	Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. <i>Blood</i> , 2011, 117, 3720-3732.	0.6	1,683
168	Histone Deacetylase Inhibitors for Treating a Spectrum of Diseases Not Related to Cancer. <i>Molecular Medicine</i> , 2011, 17, 333-352.	1.9	139
169	IL-37: a new anti-inflammatory cytokine of the IL-1 family. <i>European Cytokine Network</i> , 2011, 22, 127-147.	1.1	302
170	A clinical perspective of IL-1 β as the gatekeeper of inflammation. <i>European Journal of Immunology</i> , 2011, 41, 1203-1217.	1.6	635
171	Interleukin 37 expression protects mice from colitis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 16711-16716.	3.3	289
172	IL-1 α and IL-1 β Recruit Different Myeloid Cells and Promote Different Stages of Sterile Inflammation. <i>Journal of Immunology</i> , 2011, 187, 4835-4843.	0.4	446
173	Role of IL-1 β in type 2 diabetes. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2010, 17, 314-321.	1.2	284
174	Why not treat human cancer with interleukin-1 blockade?. <i>Cancer and Metastasis Reviews</i> , 2010, 29, 317-329.	2.7	255
175	IL-1: Discoveries, controversies and future directions. <i>European Journal of Immunology</i> , 2010, 40, 599-606.	1.6	218
176	IL-1 β regulates a novel myeloid-derived suppressor cell subset that impairs NK cell development and function. <i>European Journal of Immunology</i> , 2010, 40, 3347-3357.	1.6	264
177	IL-37 is a fundamental inhibitor of innate immunity. <i>Nature Immunology</i> , 2010, 11, 1014-1022.	7.0	735
178	Constitutively Active Inflammasome in Human Melanoma Cells Mediating Autoinflammation via Caspase-1 Processing and Secretion of Interleukin-1 β . <i>Journal of Biological Chemistry</i> , 2010, 285, 6477-6488.	1.6	259
179	Differential release of chromatin-bound IL-1 α discriminates between necrotic and apoptotic cell death by the ability to induce sterile inflammation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 2574-2579.	3.3	297
180	Anti-inflammatory Agents: Present and Future. <i>Cell</i> , 2010, 140, 935-950.	13.5	826

#	ARTICLE	IF	CITATIONS
181	Increased Cytokine Production in Interleukin-18 Receptor $\hat{\pm}$ -deficient Cells Is Associated with Dysregulation of Suppressors of Cytokine Signaling. <i>Journal of Biological Chemistry</i> , 2009, 284, 25900-25911.	1.6	38
182	$\hat{\pm}$ -1-Antitrypsin is an endogenous inhibitor of proinflammatory cytokine production in whole blood. <i>Journal of Leukocyte Biology</i> , 2009, 85, 886-895.	1.5	161
183	Bypassing Pathogen-Induced Inflammasome Activation for the Regulation of Interleukin- $\hat{1}$ $\hat{2}$ Production by the Fungal Pathogen <i>Candida albicans</i> . <i>Journal of Infectious Diseases</i> , 2009, 199, 1087-1096.	1.9	70
184	Beyond The Current Paradigm: Recent Advances in The Understanding of Sodium Handling – Guest Editors: Stanley Shaldon and Joerg Vienken: Hyperosmolar Sodium Chloride, p38 Mitogen Activated Protein and Cytokine-Mediated Inflammation. <i>Seminars in Dialysis</i> , 2009, 22, 256-259.	0.7	10
185	Immunological and Inflammatory Functions of the Interleukin-1 Family. <i>Annual Review of Immunology</i> , 2009, 27, 519-550.	9.5	2,831
186	Inflammation in Human Disease: Anticytokine Therapy. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 134-136.	2.0	17
187	The IL-1 Family Member 7b Translocates to the Nucleus and Down-Regulates Proinflammatory Cytokines. <i>Journal of Immunology</i> , 2008, 180, 5477-5482.	0.4	204
188	Ozone Exposure of Macrophages Induces an Alveolar Epithelial Chemokine Response through IL-1 $\hat{\pm}$. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2008, 38, 318-323.	1.4	47
189	Interleukin-1 $\hat{2}$ -Driven Inflammation Promotes the Development and Invasiveness of Chemical Carcinogen-Induced Tumors. <i>Cancer Research</i> , 2007, 67, 1062-1071.	0.4	258
190	A Signal for the Caspase-1 Inflammasome Free of TLR. <i>Immunity</i> , 2007, 26, 383-385.	6.6	40
191	Interleukin-18 and the Pathogenesis of Inflammatory Diseases. <i>Seminars in Nephrology</i> , 2007, 27, 98-114.	0.6	216
192	Historical insights into cytokines. <i>European Journal of Immunology</i> , 2007, 37, S34-S45.	1.6	646
193	Interleukin 1 and interleukin 18 as mediators of inflammation and the aging process. <i>American Journal of Clinical Nutrition</i> , 2006, 83, 447S-455S.	2.2	326
194	The paradox of pro-inflammatory cytokines in cancer. <i>Cancer and Metastasis Reviews</i> , 2006, 25, 307-313.	2.7	157
195	Responses of IL-18- and IL-18 receptor-deficient pancreatic islets with convergence of positive and negative signals for the IL-18 receptor. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 16852-16857.	3.3	46
196	Interleukin-1 $\hat{2}$. <i>Critical Care Medicine</i> , 2005, 33, S460-S462.	0.4	156
197	The Histone Deacetylase Inhibitor ITF2357 Reduces Production of Pro-Inflammatory Cytokines In Vitro and Systemic Inflammation In Vivo. <i>Molecular Medicine</i> , 2005, 11, 1-15.	1.9	315
198	Severe imbalance of IL-18/IL-18BP in patients with secondary hemophagocytic syndrome. <i>Blood</i> , 2005, 106, 3483-3489.	0.6	255

#	ARTICLE	IF	CITATIONS
199	Blocking IL-1 in systemic inflammation. <i>Journal of Experimental Medicine</i> , 2005, 201, 1355-1359.	4.2	454
200	CD11b+/Gr-1+ Immature Myeloid Cells Mediate Suppression of T Cells in Mice Bearing Tumors of IL-1 β -Secreting Cells. <i>Journal of Immunology</i> , 2005, 175, 8200-8208.	0.4	271
201	Interleukin-18 treatment options for inflammatory diseases. <i>Expert Review of Clinical Immunology</i> , 2005, 1, 619-632.	1.3	12
202	An IL-1 Family Member Requires Caspase-1 Processing and Signals through the ST2 Receptor. <i>Immunity</i> , 2005, 23, 461-462.	6.6	112
203	Differences between anti-tumor necrosis factor-alpha monoclonal antibodies and soluble TNF receptors in host defense impairment. <i>Journal of rheumatology Supplement, The</i> , 2005, 74, 40-7.	2.2	46
204	Differences in signaling pathways by IL-1 β and IL-18. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004, 101, 8815-8820.	3.3	208
205	Infection, fever, and exogenous and endogenous pyrogens: some concepts have changed. <i>Journal of Endotoxin Research</i> , 2004, 10, 201-222.	2.5	322
206	Interleukin-18 and the treatment of rheumatoid arthritis. <i>Rheumatic Disease Clinics of North America</i> , 2004, 30, 417-434.	0.8	31
207	Therapeutic strategies to reduce IL-1 activity in treating local and systemic inflammation. <i>Current Opinion in Pharmacology</i> , 2004, 4, 378-385.	1.7	173
208	Interleukin-1 homologues IL-1F7b and IL-18 contain functional mRNA instability elements within the coding region responsive to lipopolysaccharide. <i>Biochemical Journal</i> , 2004, 381, 503-510.	1.7	141
209	Anti-cytokine therapeutics and infections. <i>Vaccine</i> , 2003, 21, S24-S34.	1.7	126
210	Regulation of Staphylococcus epidermidis-induced IFN- γ in whole human blood: the role of endogenous IL-18, IL-12, IL-1, and TNF. <i>Cytokine</i> , 2003, 21, 65-73.	1.4	24
211	Interleukin-18 and Host Defense against Infection. <i>Journal of Infectious Diseases</i> , 2003, 187, S370-S384.	1.9	252
212	IL-1 is required for tumor invasiveness and angiogenesis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003, 100, 2645-2650.	3.3	890
213	Mechanisms of Inhibition of Collagen-Induced Arthritis by Murine IL-18 Binding Protein. <i>Journal of Immunology</i> , 2003, 170, 2100-2105.	0.4	133
214	Interleukin 18 and Interleukin 18 Binding Protein: Possible Role in Immunosuppression of Chronic Renal Failure. <i>Blood Purification</i> , 2003, 21, 258-270.	0.9	27
215	A complex of the IL-1 homologue IL-1F7b and IL-18-binding protein reduces IL-18 activity. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002, 99, 13723-13728.	3.3	215
216	The Role of Endogenous Interleukin (IL)-18, IL-12, IL-1 β , and Tumor Necrosis Factor- α in the Production of Interferon- γ Induced by <i>Candida albicans</i> in Human Whole Blood Cultures. <i>Journal of Infectious Diseases</i> , 2002, 185, 963-970.	1.9	67

#	ARTICLE	IF	CITATIONS
217	Non-LPS components of <i>Chlamydia pneumoniae</i> stimulate cytokine production through Toll-like receptor 2-dependent pathways. <i>European Journal of Immunology</i> , 2002, 32, 1188-1195.	1.6	4
218	A NOVEL IL-18BP ELISA SHOWS ELEVATED SERUM IL-18BP IN SEPSIS AND EXTENSIVE DECREASE OF FREE IL-18. <i>Cytokine</i> , 2001, 14, 334-342.	1.4	255
219	Down modulation of IL-18 expression by human papillomavirus type 16 E6 oncogene via binding to IL-18. <i>FEBS Letters</i> , 2001, 501, 139-145.	1.3	77
220	Neutralization of interleukin-18 reduces severity in murine colitis and intestinal IFN- γ and TNF- α production. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 2001, 281, R1264-R1273.	0.9	263
221	TNF receptor I is required for induction of macrophage heat shock protein 70. <i>American Journal of Physiology - Cell Physiology</i> , 2001, 281, C241-C247.	2.1	22
222	Role of interferon regulatory factor-1 in the regulation of IL-18 production and activity. <i>European Journal of Immunology</i> , 2001, 31, 369-375.	1.6	46
223	Functional Reconstitution and Regulation of IL-18 Activity by the IL-18R β Chain. <i>Journal of Immunology</i> , 2001, 166, 148-154.	0.4	78
224	Interleukin-18 Inhibits Human Immunodeficiency Virus Type 1 Production in Peripheral Blood Mononuclear Cells. <i>Journal of Infectious Diseases</i> , 2001, 184, 560-568.	1.9	42
225	Role of interferon regulatory factor-1 in the regulation of IL-18 production and activity. <i>European Journal of Immunology</i> , 2001, 31, 369-375.	1.6	2
226	Acellular components of <i>Chlamydia pneumoniae</i> stimulate cytokine production in human blood mononuclear cells. <i>European Journal of Immunology</i> , 2000, 30, 541-549.	1.6	93
227	Tumor Necrosis Factor (TNF)- α -induced Interleukin-8 in Human Blood Cultures Discriminates Neutralization by the p55 and p75 TNF Soluble Receptors. <i>Journal of Infectious Diseases</i> , 2000, 182, 1722-1730.	1.9	37
228	Measurement of Soluble and Membrane-bound Interleukin 1 Using a Fibroblast Bioassay. <i>Current Protocols in Immunology</i> , 2000, 37, Unit 6.2.	3.6	4
229	Acellular components of <i>Chlamydia pneumoniae</i> stimulate cytokine production in human blood mononuclear cells. , 2000, 30, 541.		2
230	Interleukin-11 attenuates pulmonary inflammation and vasomotor dysfunction in endotoxin-induced lung injury. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 1999, 277, L861-L867.	1.3	22
231	Increasing Levels of Interleukin (IL)-1Ra and IL-6 During the First 2 Days of Hospitalization in Unstable Angina Are Associated With Increased Risk of In-Hospital Coronary Events. <i>Circulation</i> , 1999, 99, 2079-2084.	1.6	456
232	Interleukin-18 and interleukin-1 beta: two cytokine substrates for ICE (caspase-1). <i>Journal of Clinical Immunology</i> , 1999, 19, 1-11.	2.0	423
233	Interleukin-18 Binding Protein. <i>Immunity</i> , 1999, 10, 127-136.	6.6	718
234	Interleukin-1, Interleukin-1 Receptors and Interleukin-1 Receptor Antagonist. <i>International Reviews of Immunology</i> , 1998, 16, 457-499.	1.5	682

#	ARTICLE	IF	CITATIONS
235	Interleukin-1beta, Interleukin-18, and the Interleukin-1beta Converting Enzyme. <i>Annals of the New York Academy of Sciences</i> , 1998, 856, 1-11.	1.8	447
236	Overview of interleukin-18: more than an interferon- γ inducing factor. <i>Journal of Leukocyte Biology</i> , 1998, 63, 658-664.	1.5	331
237	IL-1 β mediates leptin induction during inflammation. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 1998, 274, R204-R208.	0.9	158
238	The Pattern of Interleukin-1 β (IL-1 β) and Its Modulating Agents IL-1 Receptor Antagonist and IL-1 Soluble Receptor Type II in Acute Meningococcal Infections. <i>Blood</i> , 1997, 90, 1101-1108.	0.6	20
239	DEMONSTRATION AND CHARACTERIZATION OF TWO DISTINCT HUMAN LEUKOCYTIC PYROGENS. <i>Journal of Experimental Medicine</i> , 1974, 139, 1369-1381.	4.2	215
240	Circulating interleukin-37 declines with aging in healthy humans: relations to healthspan indicators and IL37 gene SNPs. <i>GeroScience</i> , 0, , .	2.1	5